A Rare Infectious Complication of a Treatment with Biologics: Disseminated Cutaneous Leishmaniasis Associated with Adalimumab

Kerasia-Maria Plachouri; Maria Gkermpesi; Eleftheria Vryzaki; Pinelopi Kollyrou; Markos Marangos; Sophia Georgiou

doi:10.5826/dpc.1003a61

A Rare Infectious Complication of a Treatment with Biologics: Disseminated Cutaneous Leishmaniasis Associated with Adalimumab

Authors

Kerasia-Maria Plachouri Department of Dermatology, University General Hospital of Patras, Greece
Maria Gkermpesi Department of Pathology, University General Hospital of Patras, Greece
Eleftheria Vryzaki Department of Dermatology, University General Hospital of Patras, Greece
Pinelopi Kollyrou Department of Dermatology, University General Hospital of Patras, Greece
Markos Marangos Division of Infectious Diseases, University General Hospital of Patras, Greece
Sophia Georgiou Department of Dermatology, University General Hospital of Patras, Greece

Keywords:

adalimumab, leishmaniasis, immunosuppression, psoriasis, biologics

References

Bosch-Nicolau P, Ubals M, Salvador F, et al. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin: a switch in clinical expression. PLoS Negl Trop Dis. 2019;13(8):e0007708. https://doi.org/10.1371/journal.pntd.0007708

Stamm LV. Human migration and leishmaniasis—on the move. JAMA Dermatol. 2016;152(4):373-374. https://doi.org/10.1001/jamadermatol.2015.4765

Downloads

Published

2020-06-29

Issue

2020 Vol 10, No 3 | July

Section

Letter

License

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

Plachouri KM, Gkermpesi M, Vryzaki E, Kollyrou P, Marangos M, Georgiou S. A Rare Infectious Complication of a Treatment with Biologics: Disseminated Cutaneous Leishmaniasis Associated with Adalimumab. Dermatol Pract Concept. 2020;10(3):e2020061. doi:10.5826/dpc.1003a61